Global Myelodysplastic Syndrome Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028

Published on: 2022-01-10 | No of Pages : 320 | Industry : Medical Care

Publisher : GRD Survey | Format : PDF

Global Myelodysplastic Syndrome Industry Outlook 2022: Overview, Opportunities, Key Companies and Forecast to 2028

Executive Summary

According to GRD Survey data, the global Myelodysplastic Syndrome market is estimated at million US$ in 2021 and is expected to million US$ by the end of 2028, growing at a CAGR of % in the forecast period from 2022 to 2028.

This report studies the Myelodysplastic Syndrome market dynamics from angles such as new entries, mergers and acquisitions, fundings, exit and major technology breakthroughs. Market performance is evaluated through market size (Million USD) by players, regions, product types and end industries. This report also studies the global market competition landscape, market drivers and trends, opportunities and challenges, risks and entry barriers, sales channels, distributors and Porter's Five Forces Analysis.

Geographically, this report is segmented into several key regions, with revenue, market share and growth Rate of Myelodysplastic Syndrome in these regions, from 2016 to 2027, covering
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Italy, Spain and Russia, etc.)
Asia-Pacific (China, Japan, Korea, Southeast Asia, India, Australia)
South America (Brazil, Argentina, Colombia, etc.)
Middle East and Africa (Turkey, Saudi Arabia, South Africa, etc.)

Market Snapshot, By Product Type
Hypomethylating Agents
Immunomodulatory Drugs
Anti-anemics

Market Snapshot, By Application
Hospital
Clinic

Main Market Players Analyzed in this report, including:
TetraLogic Pharmaceuticals
Targazyme
Sunesis Pharmaceuticals
Sumitomo Dainippon Pharma
Strategia Therapeutics
Otsuka
Onconova Therapeutics
Novartis
Mirati Therapeutics
Kiadis Pharma
KaloBios Pharmaceuticals
GlaxoSmithKline
Gamida Cell
Eli-lilly
CTI BioPharma
Cornerstone Pharmaceuticals
Celgene
Celator Pharmaceuticals
Bellicum Pharmaceuticals
Astex
Actinium Pharmaceuticals
Acceleron Pharma

The study objectives of this report are:
To study and analyze the global Myelodysplastic Syndrome market size (Million USD) by company, key regions/countries, products and application, history data from 2016 to 2020, and forecast to 2027.
To understand industry structure of Myelodysplastic Syndrome market by identifying its various subsegments.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To identify the key global Myelodysplastic Syndrome manufacturers and regional typical players, to define, describe and analyze their sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Myelodysplastic Syndrome market with respect to individual growth trends, future prospects, and their contribution to the total market.
To project the value and volume of Myelodysplastic Syndrome submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.

In this study, the years considered to estimate the market size of Myelodysplastic Syndrome are as follows:
History Year: 2016-2020
Base Year: 2020
Estimated Year: 2021
Forecast Year 2021 to 2027

This report includes the estimation of market size from top-down approach by analyzing major submarkets and their major driving factors, and verified from bottom-up approaches. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified from primary sources.

For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Key Stakeholders Considered in the study:
Raw material vendors
Distributors/traders/wholesalers/suppliers
Regulatory authorities, including government agencies and NGO
Commercial research & development (R&D) institutions
Importers and exporters
Government organizations, research organizations, and consulting firms
Trade/Industrial associations
End-use industries

Table of Content

Table of Contents

1 Market Definition & Scope
1.1 Definition & Scope
1.2 Myelodysplastic Syndrome Product Specifications
1.3 Main Events (Entry, M&A, Exit, Technology and Capital Activity)
1.4 Global Myelodysplastic Syndrome Market Performance and Outlook

2 Market Development Performance under COVID-19
2.1 Influencing Factors of Industry Development in the Next Five Years
2.1.1 Drivers
2.1.2 Restraints
2.1.3 Opportunities
2.2 Porter’s Five Forces Analysis
2.3 Comparison of Alternatives and Myelodysplastic Syndrome

3 3 Industrial Lift Cycle and Main Buyers Analysis
3.1 Industry Life Cycle Analysis
3.2 Key Buying Industries/Consumers
3.2.1 Major Buyers in Hospital
3.2.2 Major Buyers in Clinic

4 Market Segment: by Type
4.1 Myelodysplastic Syndrome Type Introduction
4.1.1 Hypomethylating Agents
4.1.2 Immunomodulatory Drugs
4.1.3 Anti-anemics
4.2 Global Myelodysplastic Syndrome Revenue by Type 2016-2021

5 Market Segment: by Application
5.1 Myelodysplastic Syndrome Type Introduction
5.1.1 Hospital
5.1.2 Clinic
5.2 Global Myelodysplastic Syndrome Revenue by Application 2016-2021

6 Marke Segment: by Region
6.1 Global Myelodysplastic Syndrome Market by Region
6.2 North America Myelodysplastic Syndrome Market 2016-2021
6.3 Europe Myelodysplastic Syndrome Market 2016-2021
6.4 Asia Pacific Myelodysplastic Syndrome Market 2016-2021
6.5 South America Myelodysplastic Syndrome Market 2016-2021
6.6 Middle East and Africa Myelodysplastic Syndrome Market 2016-2021

7 North America
7.1 North America Myelodysplastic Syndrome Market by Country 2016-2021
7.2 United States
7.3 Canada
7.4 Mexico

8 Europe
8.1 Europe Myelodysplastic Syndrome Market by Country 2016-2021
8.2 Germany
8.3 France
8.4 UK
8.5 Italy
8.6 Russia
8.7 Spain

9 Asia Pacific
9.1 Asia Pacific Myelodysplastic Syndrome Market by Country 2016-2021
9.2 China
9.3 Japan
9.4 Korea
9.5 Southeast Asia
9.6 India
9.7 Australia

10 South America
10.1 South America Myelodysplastic Syndrome Market by Country 2016-2021
10.2 Brazil
10.3 Argentina
10.4 Colombia

11 Middle East and Africa
11.1 Middle East and Africa Myelodysplastic Syndrome Market by Country 2016-2021
11.2 Turkey
11.3 Saudi Arabia
11.4 South Africa

12 Key Participants Company Information
12.1 TetraLogic Pharmaceuticals
12.1.1 TetraLogic Pharmaceuticals Company Information
12.1.2 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.1.3 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.1.4 TetraLogic Pharmaceuticals Key Development
12.2 Targazyme
12.2.1 Targazyme Company Information
12.2.2 Targazyme Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.2.3 Targazyme Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.2.4 Targazyme Key Development
12.3 Sunesis Pharmaceuticals
12.3.1 Sunesis Pharmaceuticals Company Information
12.3.2 Sunesis Pharmaceuticals Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.3.3 Sunesis Pharmaceuticals Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.3.4 Sunesis Pharmaceuticals Key Development
12.4 Sumitomo Dainippon Pharma
12.4.1 Sumitomo Dainippon Pharma Company Information
12.4.2 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.4.3 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.4.4 Sumitomo Dainippon Pharma Key Development
12.5 Strategia Therapeutics
12.5.1 Strategia Therapeutics Company Information
12.5.2 Strategia Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.5.3 Strategia Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.5.4 Strategia Therapeutics Key Development
12.6 Otsuka
12.6.1 Otsuka Company Information
12.6.2 Otsuka Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.6.3 Otsuka Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.6.4 Otsuka Key Development
12.7 Onconova Therapeutics
12.7.1 Onconova Therapeutics Company Information
12.7.2 Onconova Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.7.3 Onconova Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.7.4 Otsuka Key Development
12.9 Mirati Therapeutics
12.9.1 Mirati Therapeutics Company Information
12.9.2 Mirati Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.9.3 Mirati Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.9.4 Mirati Therapeutics Key Development
12.8 Novartis
12.8.1 Novartis Company Information
12.8.2 Novartis Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.8.3 Novartis Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.8.4 Novartis Key Development
12.11 KaloBios Pharmaceuticals
12.11.1 KaloBios Pharmaceuticals Company Information
12.11.2 KaloBios Pharmaceuticals Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.11.3 KaloBios Pharmaceuticals Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.11.4 KaloBios Pharmaceuticals Key Development
12.12 GlaxoSmithKline
12.12.1 GlaxoSmithKline Company Information
12.12.2 GlaxoSmithKline Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.12.3 GlaxoSmithKline Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.12.4 GlaxoSmithKline Key Development
12.13 Gamida Cell
12.13.1 Gamida Cell Company Information
12.13.2 Gamida Cell Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.13.3 Gamida Cell Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.13.4 Gamida Cell Key Development
12.14 Eli-lilly
12.14.1 Eli-lilly Company Information
12.14.2 Eli-lilly Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.14.3 Eli-lilly Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.14.4 Eli-lilly Key Development
12.15 CTI BioPharma
12.15.1 CTI BioPharma Company Information
12.15.2 CTI BioPharma Myelodysplastic Syndrome Product Portfolio, Specification and Application
12.15.3 CTI BioPharma Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
12.15.4 CTI BioPharma Key Development
12.17 Celgene
12.18 Celator Pharmaceuticals
12.19 Bellicum Pharmaceuticals
12.20 Astex
12.21 Actinium Pharmaceuticals
12.22 Acceleron Pharma

13 Global Myelodysplastic Syndrome Market Forecast by Region by Type and by Application
13.1 Global Myelodysplastic Syndrome Revenue Forecast 2022-2027
13.2 Global Myelodysplastic Syndrome Forecast by Regions
13.3 Global Myelodysplastic Syndrome Forecast by Type
13.4 Global Myelodysplastic Syndrome Forecast by Application

14 Analyst Views and Conclusions

15 Methodology and Data Source
15.1 Methodology
15.2 Research Data Source
15.2.1 Secondary Data
15.2.2 Primary Data
15.2.3 Market Size Estimation
15.3 Legal Disclaimer

List of Figure

List of Tables

Table 1: Global Myelodysplastic Syndrome Production Specifications
Table 2: Drivers in Myelodysplastic Syndrome Market
Table 3: Restraints Myelodysplastic Syndrome Market
Table 4: Opportunity in Myelodysplastic Syndrome Market
Table 5: Comparion of Alternative and Myelodysplastic Syndrome
Table 6: Myelodysplastic Syndrome Raw Materials Key Suppliers List
Table 7: Myelodysplastic Syndrome Distributors List
Table 8: Myelodysplastic Syndrome Major Buyers in Application One
Table 9: Myelodysplastic Syndrome Major Buyers in Application Two
Table 10: Myelodysplastic Syndrome Major Buyers in Application Three
Table 11: Global Myelodysplastic Syndrome Revenue (Million USD) by Type 2016-2021
Table 12: Global Myelodysplastic Syndrome Revenue Market Share by Type 2016-2021
Table 18: Global Myelodysplastic Syndrome Revenue (Million USD) by Application 2016-2021
Table 19: Global Myelodysplastic Syndrome Revenue Market Share by Application 2016-2021
Table 20: Global Myelodysplastic Syndrome Revenue (Million USD) by Region 2016-2021
Table 21: Global Myelodysplastic Syndrome Revenue Market Share by Region 2016-2021
Table 22: North America Myelodysplastic Syndrome Revenue (Million USD) by Country 2016-2021
Table 23: North America Myelodysplastic Syndrome Revenue Market Share by Country 2016-2021)
Table 24: Europe Myelodysplastic Syndrome Revenue (Million USD) by Country 2016-2021
Table 25: Europe Myelodysplastic Syndrome Revenue Market Share by Country 2016-2021)
Table 26: Asia Pacific Myelodysplastic Syndrome Revenue (Million USD) by Country 2016-2021
Table 27: Asia Pacific Myelodysplastic Syndrome Revenue Market Share by Country 2016-2021)
Table 28: South America Myelodysplastic Syndrome Revenue (Million USD) by Country 2016-2021
Table 29: South America Myelodysplastic Syndrome Revenue Market Share by Country 2016-2021)
Table 30: Middle East and Africa Myelodysplastic Syndrome Revenue (Million USD) by Country 2016-2021
Table 31: Middle East and Africa Myelodysplastic Syndrome Revenue Market Share by Country 2016-2021)
Table 32 TetraLogic Pharmaceuticals Company Information
Table 33 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 34 TetraLogic Pharmaceuticals Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 35 Targazyme Company Information
Table 36 Targazyme Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 37 Targazyme Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 38 Sunesis Pharmaceuticals Company Information
Table 39 Sunesis Pharmaceuticals Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 40 Sunesis Pharmaceuticals Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 41 Sumitomo Dainippon Pharma Company Information
Table 42 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 43 Sumitomo Dainippon Pharma Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 44 Strategia Therapeutics Company Information
Table 45 Strategia Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 46 Strategia Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 47 Otsuka Company Information
Table 48 Otsuka Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 49 Otsuka Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 50 Onconova Therapeutics Company Information
Table 51 Onconova Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 52 Onconova Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 53 Novartis Company Information
Table 54 Novartis Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 55 Novartis Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 56 Mirati Therapeutics Company Information
Table 57 Mirati Therapeutics Myelodysplastic Syndrome Product Portfolio, Specification and Application
Table 58 Mirati Therapeutics Myelodysplastic Syndrome Revenue and Gross Margin (2019-2021)
Table 59: Global Myelodysplastic Syndrome Revenue (Million USD) Forecast by Region (2022-2027)
Table 60: Global Myelodysplastic Syndrome Revenue Market Share Forecast by Region (2022-2027)
Table 61: Global Myelodysplastic Syndrome Revenue (Million USD) Forecast by Type (2022-2027)
Table 62: Global Myelodysplastic Syndrome Revenue Market Share Forecast by Type (2022-2027)
Table 63: Global Myelodysplastic Syndrome Revenue (Million USD) Forecast by Application (2022-2027)
Table 64: Global Myelodysplastic Syndrome Revenue Market Share Forecast by Application (2022-2027)


List of Figures

Figure 1: Myelodysplastic Syndrome Picture
Figure 2: Global Myelodysplastic Syndrome Market Size (Million USD) and Growth Rate (2016-2027)
Figure 3: Porter's Five Forces Analysis
Figure 4: Myelodysplastic Syndrome Industry Life Cycle
Figure 5: Product Picture of Hypomethylating Agents
Figure 6: Product Picture of Immunomodulatory Drugs
Figure 9: Global Myelodysplastic Syndrome Revenue Market Share by Type, 2020
Figure 10: Myelodysplastic Syndrome in Hospital
Figure 11: Global Myelodysplastic Syndrome Market: Hospital 2016-2021
Figure 12: Myelodysplastic Syndrome in Clinic
Figure 13: Global Myelodysplastic Syndrome Market: Clinic 2016-2021
Figure 14: Global Myelodysplastic Syndrome Revenue Market Share by Application, 2020
Figure 15: Global Myelodysplastic Syndrome Revenue Market Share by Region 2016-2021
Figure 16: North America Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 7: Europe Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 8: Asia Pacific Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 9: South America Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 10: Middle East and Africa Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 11: North America Myelodysplastic Syndrome Revenue Market Share by Country, 2020
Figure 12: United States Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 13: Canada Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 14: Mexico Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 15: Europe Myelodysplastic Syndrome Revenue Market Share by Country, 2020
Figure 16: Germany Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 17: France Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 18: UK Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 19: Italy Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 20: Russia Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 21: Spain Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 22: Asia Pacific Myelodysplastic Syndrome Revenue Market Share by Country, 2020
Figure 23: China Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 24: Japan Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 25: Korea Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 26: Southeast Asia Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 27: India Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 28: Australia Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 29: South America Myelodysplastic Syndrome Revenue Market Share by Country, 2020
Figure 30: Brazil Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 31: Argentina Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 32: Colombia Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 33: Middle East and Africa Myelodysplastic Syndrome Revenue Market Share by Country, 2020
Figure 34: Turkey Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 35: Saudi Arabia Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 36: South Africa Myelodysplastic Syndrome Revenue (Million USD) Status 2016-2021
Figure 37: TetraLogic Pharmaceuticals Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 38: Targazyme Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 39: Sunesis Pharmaceuticals Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 40: Sumitomo Dainippon Pharma Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 41: Strategia Therapeutics Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 42: Otsuka Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 43: Onconova Therapeutics Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 44: Novartis Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 45: Mirati Therapeutics Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 46: Kiadis Pharma Myelodysplastic Syndrome Revenue Market Share Globally (2019-2021)
Figure 47: Global Myelodysplastic Syndrome Revenue (Million USD) Forecast (2022-2027)

Select User License

$3980 Single Licence
$5950 Enterprise Licence
$7960 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries